Arrowstreet Capital, Limited Partnership Concert Pharmaceuticals, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$4.86 - $13.07 $235,481 - $633,280	-48,453 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$9.48 - $12.84 $136,512 - $184,896	-14,400 Reduced 22.91%	48,453 $612,000
Q3 2020 Nov 12, 2020	BUY	$8.67 - $10.82 $294,806 - $367,912	34,003 Added 117.86%	62,853 $617,000
Q2 2020 Aug 12, 2020	BUY	$7.8 - $11.52 $52,447 - $77,460	6,724 Added 30.39%	28,850 $287,000
Q1 2020 May 15, 2020	BUY	$5.98 - $13.09 $49,191 - $107,678	8,226 Added 59.18%	22,126 $196,000
Q4 2019 Feb 13, 2020	BUY	$5.71 - $9.22 $79,369 - $128,158	13,900 New	13,900 $128,000
Q4 2018 Feb 14, 2019	SELL	$11.25 - $16.17 $3.35 Million - $4.82 Million	-297,864 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$12.82 - $17.88 $48,536 - $67,693	-3,786 Reduced 1.26%	297,864 $4.42 Million
Q2 2018 Aug 14, 2018	BUY	$16.83 - $21.66 $163,250 - $210,102	9,700 Added 3.32%	301,650 $5.08 Million
Q1 2018 May 14, 2018	BUY	$19.24 - $28.03 $3.53 Million - $5.14 Million	183,250 Added 168.58%	291,950 $6.69 Million
Q4 2017 Feb 09, 2018	BUY	$13.96 - $29.05 $1.52 Million - $3.16 Million	108,700	108,700 $2.81 Million

Ticker CNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,934,600
Description
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has s...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.